<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; domestic</title>
	<atom:link href="http://www.tapanray.in/tag/domestic/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>When ‘Vikshit Bharat’ Rings Hollow: A Tragedy That Exposes India’s Uneven Progress</title>
		<link>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress</link>
		<comments>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/#comments</comments>
		<pubDate>Fri, 10 Oct 2025 11:25:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cough]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[hollow]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rings]]></category>
		<category><![CDATA[syrup]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tragedy]]></category>
		<category><![CDATA[Vikshit Bharat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10978</guid>
		<description><![CDATA[India’s vision of Vikshit Bharat promises inclusive growth and modern progress. Yet, when children die from contaminated cough syrup, that dream rings hollow. This article asks the hard question: can a nation truly be “developed” when its weakest citizens still fall victim &#8230; <a href="http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Pharma Growth Strategy Now Extends Beyond Human Intelligence</title>
		<link>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-pharma-growth-strategy-now-extends-beyond-human-intelligence</link>
		<comments>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/#comments</comments>
		<pubDate>Fri, 08 Dec 2023 06:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[examples]]></category>
		<category><![CDATA[generative]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Microsoft]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10844</guid>
		<description><![CDATA[That the drug Industry’s growth strategy now extends beyond human intelligence, across the value chain, are being vindicated by several reports, around the world since several years. Illustratively, on September 1, 2019, Novartis and Microsoft announced a multiyear alliance which will leverage data &#8230; <a href="http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-pharma-growth-strategy-now-extends-beyond-human-intelligence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is India A Success Story With Biosimilar Drugs?</title>
		<link>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-india-a-success-story-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 25 Feb 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9422</guid>
		<description><![CDATA[How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse &#8211; but the initiative is not a current one. This journey commenced decades ago &#8230; <a href="http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Key Drivers And Long-Term Impact of Pharma M&amp;A in India</title>
		<link>http://www.tapanray.in/key-drivers-and-long-term-impact-of-pharma-ma-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=key-drivers-and-long-term-impact-of-pharma-ma-in-india</link>
		<comments>http://www.tapanray.in/key-drivers-and-long-term-impact-of-pharma-ma-in-india/#comments</comments>
		<pubDate>Mon, 21 May 2018 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entity]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[inbound]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[long-term]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[merged]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[outbound]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8959</guid>
		<description><![CDATA[Corporate M&#38;A is increasingly considered an integral part of the organization’s growth strategy for value creation, by a large number of pharma companies, across the world. In tandem, it throws open many other doors of opportunities, such as reduction of &#8230; <a href="http://www.tapanray.in/key-drivers-and-long-term-impact-of-pharma-ma-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/key-drivers-and-long-term-impact-of-pharma-ma-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Managing Pharma Investors’ Expectations When The Chips Are Down</title>
		<link>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=managing-pharma-investors-expectations-when-the-chips-are-down</link>
		<comments>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/#comments</comments>
		<pubDate>Sun, 18 Jun 2017 23:34:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[activist]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chips]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Investors]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8282</guid>
		<description><![CDATA[Triggered by several critical factors, over a relatively short period of time, a downward spiral is visible with most Indian Pharma stocks, with a significant erosion in market capitalization of many large players in the country. A set of important &#8230; <a href="http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Even Smaller Countries Now Question Indian Drug Quality Standard</title>
		<link>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=even-smaller-countries-now-question-indian-drug-quality-standard</link>
		<comments>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/#comments</comments>
		<pubDate>Sun, 04 Dec 2016 23:42:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Consumption]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[smaller]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Vietnam]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8001</guid>
		<description><![CDATA[India has over 135 US-FDA approved pharmaceutical manufacturing units, at present. This number is very significant ranking second behind the United States, and was driving the growth of generic drug exports in the top pharma market of the world. Riding &#8230; <a href="http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes&#8230;and Avoids Ruffling Feathers?</title>
		<link>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers</link>
		<comments>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/#comments</comments>
		<pubDate>Mon, 19 Aug 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[feathers]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illusionary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[matrix]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[oligopolistic]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[protectionism]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[retrograde]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tweaking]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vetoed]]></category>
		<category><![CDATA[vetoes veto]]></category>
		<category><![CDATA[wrong]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3241</guid>
		<description><![CDATA[An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department &#8230; <a href="http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the Wonderland of Pharma Generics: Some Steps In, Some Steps Over the Line</title>
		<link>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line</link>
		<comments>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/#comments</comments>
		<pubDate>Mon, 10 Jun 2013 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[blockbusters]]></category>
		<category><![CDATA[blocking]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[disparaging]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[entering]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Holland]]></category>
		<category><![CDATA[Impax]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NUT]]></category>
		<category><![CDATA[Opana]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[OxyContin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Purdue]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[TevaSante]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[ZydusCadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2234</guid>
		<description><![CDATA[To scale-up access to healthcare, especially for the marginalized population of any country, greater access to affordable generic drugs will always remain fundamental, besides improving healthcare infrastructure and its delivery mechanism. Thus, there should be a robust mechanism across the &#8230; <a href="http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The domestic API players are fast losing their dominance in the Indian API market</title>
		<link>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market</link>
		<comments>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/#comments</comments>
		<pubDate>Mon, 24 Oct 2011 00:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[dominance]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[losing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[their]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=184</guid>
		<description><![CDATA[There are two broad categories of markets for the Active Pharmaceutical Ingredients (API) across the world namely, highly regulated and semi regulated markets. Countries like, USA, Europe and Japan will fall under highly regulated category with high entry barriers for &#8230; <a href="http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Europe: now emerging as a more preferred market for the domestic Indian Pharmaceutical Industry</title>
		<link>http://www.tapanray.in/europe-now-emerging-as-a-more-preferred-market-for-the-domestic-indian-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=europe-now-emerging-as-a-more-preferred-market-for-the-domestic-indian-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/europe-now-emerging-as-a-more-preferred-market-for-the-domestic-indian-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 03 Aug 2009 01:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[as]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[preferred]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=818</guid>
		<description><![CDATA[Since almost last 30 years the Pharmaceutical Industry of India has been a net foreign exchange earner. Deutche Bank Researchindicates that over the last ten years the export surplus has widened from EUR 370 million to EUR 2 billion.Around 80% &#8230; <a href="http://www.tapanray.in/europe-now-emerging-as-a-more-preferred-market-for-the-domestic-indian-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/europe-now-emerging-as-a-more-preferred-market-for-the-domestic-indian-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
